Pulmonary Arterial Hypertension Treatment Market to Make Great Impact in Near Future by 2026

According to World Health Organization (WHO), raised blood pressure is estimated to cause 7.5 million deaths around the world. Hypertension is a risk factor for coronary heart disease, ischemic and hemorrhagic stroke. In addition complications of hypertension includes peripheral vascular disease, heart failure, renal impairment, retinal hemorrhage and visual impairment.

Having family history of Pulmonary Arterial Hypertension, change in life style, unhealthy food, and physical inactivity causes hypertension.

To treat pulmonary atrial hypertension following treatments are available

Medication

Surgeries

Medications include blood vessel dilators (vasodilators), Endothelin receptor antagonists, phosphodiesterase III inhibitors, calcium channel blockers, anticoagulants, diuretics.

Browse Full Report@ http://www.futuremarketinsights.com/reports/pulmonary-arterial-hypertension-treatment-market

Atrial septostomy and Transplantation are the two surgery option for patients who suffering from severe pulmonary atrial hypertension. Transplantation is may be an option for younger people who are suffering from idiopathic pulmonary hypertension.

Pulmonary Arterial Hypertension Treatment Market: Drivers and Restraints

According to World Health Organization, Globally the prevalence rate of hypertension was 40% in adults who aged 25 and above in the year 2008. The prevalence rate is high in Africa region and Americas having less prevalence rate in hypertension. Change in the life style, family history of pulmonary atrial hypertension, unhealthy food, and physical inactivity are the risk factors for hypertension as well as drivers for this market. Raising the geriatric population around the world also driver for pulmonary atrial hypertension treatment market. Guidelines form government organizations such as World Health Organization (WHO), Center for Disease Control and Prevention plays a major role in the prevention of pulmonary atrial hypertension...